Effects of Lespedeza Cuneata aqueous extract on testosterone-induced prostatic hyperplasia

References

• Ahn D. 1998. Illustrated book of Korean medicinal herbs. Seoul: Kyohaksa.
   Google Scholar
• Andriole G, Bruchovsky N, Chung LW, Matsumoto AM, Rittmaster R, Roehrborn C, Russell D, Tindall D. 2004. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 172:1399–1403.
   PubMed Web of Science ®Google Scholar
• Babu SV, Veeresh B, Patil AA, Warke Y. 2010. Lauric acid and myristic acid prevent testosterone induced prostatic hyperplasia in rats. Euro Pharm. 626:262–265.
   PubMed Web of Science ®Google Scholar
• Boget S, Cereser C, Parvaz P, Leriche A, Revol A. 2001. Fibroblast growth factor receptor 1 (FGFR1) is over-expressed in benign prostatic hyperplasia whereas FGFR2-iiic and FGFR3 are not. Euro Endocrinol. 145:303–310.
   Web of Science ®Google Scholar
• Bullock TL, Andriole GL Jr. 2006. Emerging drug therapies for benign prostatic hyperplasia. Expert Opin Emerg Drugs. 11:111–123.
   PubMedGoogle Scholar
• Cauci S, Chiriaco G, Cecchin E, Toffoli G, Xodo S, Stinco G, Trombetta C. 2017. Androgen receptor (AR) gene (CAG)n (GGN)n length polymorphisms and symptoms in young males with long lasting adverse effects after finasteride use against androgenic lopecia. Sex Med. 5:e61–e71.
   PubMed Web of Science ®Google Scholar
• Deng F, Chang J, Zhang JS. 2007. New flavonoids and other constituents from Lespedeza cuneata. J Asian Nat Prod Res. 9:655–658.
   PubMed Web of Science ®Google Scholar
• Ding JL, Lim IJ, Lee HD, Cha WS. 2006. Analysis of minerals, amino acids, and vitamin of Lespedeza cuneata. KSBB J. 21:414–417.
   Google Scholar
• Ekman P. 1989. BPH epidemiology and risk factors. Prostate Suppl. 2:23–31.
   PubMedGoogle Scholar
• Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, et al. 2012. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol. 61:994–1003.
   PubMed Web of Science ®Google Scholar
• Gilbert TD Jr, Davis EA, Ollendorf DA. 2006. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care. 12:S99–S110.
   PubMed Web of Science ®Google Scholar
• Gravas S, Oelke M. 2010. Current status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH. World J Urol. 28:9–15.
   PubMed Web of Science ®Google Scholar
• Horton R, Hsieh P, Barberia J, Pages L, Cosgrove M. 1975. Altered blood androgens in elderly men with prostate hyperplasia. J Clin Endocrinol Metab. 41:793–796.
   PubMed Web of Science ®Google Scholar
• Huang KC. 1998. The pharmacology of Chinese herbs. Taylor&Francis Group.
   Google Scholar
• Izumi K, Mizokami A, Lin WJ, Lai KP, Chang C. 2013. Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 182:1942–1949.
   PubMed Web of Science ®Google Scholar
• Kang H, Ku SK, Jung B, Bae JS. 2015. Anti-inflammatory effects of vicenin-2 and scolymoside in vitro and in vivo. Inflamm Res. 64:1005–1021.
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim MJ. 2010. In vitro anti-oxidant activity of Lespedeza cuneata methanolic extracts. J Med Plants Res. 4:674–679.
   Google Scholar
• Kramer G, Mitteregger D, Marberger M. 2007. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol. 51:1202–1216.
   PubMed Web of Science ®Google Scholar
• Kramer G, Steiner GE, Handisurya A, Stix U, Haitel A, Knerer B, Gessl A, Lee C, Marberger M. 2002. Increased expression of lymphocyte-derived cytokines in benign hyperplastic prostate tissue, identification of the producing cell types, and effect of differentially expressed cytokines on stromal cell proliferation. Prostate. 52:43–58.
   PubMed Web of Science ®Google Scholar
• Lai J, Xia Q, Zhang X, Zhao G, Xu S, Zheng D. 2004. [Expression and significance of PCNA and p27 in benign prostate hypertrophy and prostate carcinoma]. Zhonghua Zhong Liu Za Zhi. 26:476–478. Chinese.
   PubMedGoogle Scholar
• Lee H, Jung JY, Hwangbo M, Ku SK, Kim YW, Jee SY. 2013. Anti-inflammatory effects of Lespedeza cuneata in vivo and in vitro. Korea J Herbol. 28:83–92.
   Google Scholar
• Lee SJ, Hossaine MA, Park SC. 2016. A potential anti-inflammation activity and depigmentation effect of Lespedeza bicolor extract and its fractions. Saudi Biol Sci. 23:9–14.
   PubMed Web of Science ®Google Scholar
• Lucia MS, Lambert JR. 2008. Growth factors in benign prostatic hyperplasia: Basic science implications. Curr Urol Rep. 9:272–278.
   PubMedGoogle Scholar
• Matsuura S, Iinuma M, Ito E, Takami H, Kage K. 1978. [Studies on the constituents of the useful plants. VIII. The constituents of Lespedeza cuneata G. Don (author's transl)]. Yakugaku Zasshi. 98:1542–1544. Japanese.
   PubMed Web of Science ®Google Scholar
• McVary KT. 2007. A review of combination therapy in patients with benign prostatic hyperplasia. Clin Ther. 29:387–398.
   PubMed Web of Science ®Google Scholar
• Miller J, Tarter T. 2009. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Inter Aging. 4:251–258.
   PubMed Web of Science ®Google Scholar
• Nagaprashantha LD, Vatsyayan R, Singhal J, Fast S, Roby R, Awasthi S, Singhal SS. 2011. Anti-cancer effects of noverl flavonoid vicenin-2 as a single agent and in synergistin combination with docetaxel in prostate cancer. Biochem Pharmacol. 82:1100–1109.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. 2008. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the reduce trial. Eur Urol. 54:1379–1384.
   PubMed Web of Science ®Google Scholar
• Paba S, Frau R, C Godar S, Devoto P, Marrosu F, Bortolato M. 2011. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Curr Pharm Design. 17:151–167.
   PubMed Web of Science ®Google Scholar
• Ropiquet F, Giri D, Lamb DJ, Ittmann M. 1999. FGF7 and FGF2 are increased in benign prostatic hyperplasia and are associated with increased proliferation. J Urol. 162:595–599.
   PubMed Web of Science ®Google Scholar
• Rudkowska I, AbuMweis SS, Nicolle C, Jones PJ. 2008. Cholesterol-lowering efficacy of plant sterols in low-fat yogurt consumed as a snack or with a meal. J Am Coll Nutr. 27:588–595.
   PubMed Web of Science ®Google Scholar
• Sáez C, González Baena AC, Japón MA, Giráldez J, Segura DI, Rodríguez Vallejo JM, González Esteban J, Miranda G, Torrubia F. 1999. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. Prostate. 40:83–88.
   PubMed Web of Science ®Google Scholar
• Sharad SS, Divya J, Preeti S, Sanjay A, Jyotsana S, David H. 2017. Targeting the mercapturic acid pathway and vicenin-2 for prevention of prostatic cancer. Biochim Biophys Acta Rev Cancer. 1868:167–175.
   PubMed Web of Science ®Google Scholar
• Shin IS, Lee MY, Ha HK, Seo CS, Shin HK. 2012. Inhibitory effect of yukmijihwang-tang, a traditional herbal formula against testosterone-induced benign prostatic hyperplasia in rats. BMC Complement Alter Med. 12:48–54.
   PubMed Web of Science ®Google Scholar
• Theyer G, Kramer G, Assmann I, Sherwood E, Preinfalk W, Marberger M, Zechner O, Steiner G. 1992. Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia. Lab Invest. 66:96–107.
   PubMed Web of Science ®Google Scholar
• Vikram A, Kushwaha S, Jena G. 2011. Relative influence of testosterone and insulin in the regulation of prostatic cell proliferation and growth. Steroids. 76:416–423.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Ishani A, MacDonald R, Stark G, Mulrow CD, Lau J. 2000. Beta sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. (2):CD001043.
   Google Scholar
• Xu DH, Wang LH, Mei XT, Li BJ, Lv JL, Xu SB. 2014. Protective effects of seahorse extracts in a rat castration and testosterone-induced benign prostatic hyperplasia model and mouse oligospermatism model. Environ Toxicol Pharm. 37:679–688.
   PubMed Web of Science ®Google Scholar
• Zhong W, Peng J, He H, Wu D, Han Z, Bi X, Dai Q. 2008. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med. 31:8–15.
   Web of Science ®Google Scholar